Cargando…

Correction to: MYL-1402O: A Bevacizumab Biosimilar

Detalles Bibliográficos
Autor principal:	Lee, Arnold
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217870/ https://www.ncbi.nlm.nih.gov/pubmed/35437710 http://dx.doi.org/10.1007/s11523-022-00882-1

Ejemplares similares

MYL-1402O: A Bevacizumab Biosimilar
por: Lee, Arnold
Publicado: (2021)

A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab
por: Hummel, Matthew, et al.
Publicado: (2021)

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer
por: Socinski, Mark A., et al.
Publicado: (2021)

Correction to: SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Correction to: MYL1501D Insulin Glargine: A Review in Diabetes Mellitus
por: Hoy, Sheridan M.
Publicado: (2020)

Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine
por: Goyal, Parag, et al.
Publicado: (2021)

A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab
por: Yang, Charlie, et al.
Publicado: (2022)

Nezahualcóyotl, Acolmiztli, 1402-1472
por: Alva Ixtlilxóchitl, Fernando de, 1402-1472
Publicado: (1972)

Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
por: Markus, Richard, et al.
Publicado: (2017)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Correction to: GP2015: An Etanercept Biosimilar
por: Deeks, Emma D.
Publicado: (2018)

Correction: Preparing for the incoming wave of biosimilars in oncology
Publicado: (2018)

SB8: A Bevacizumab Biosimilar
por: Syed, Yahiya Y.
Publicado: (2020)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Randomized phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H in the prophylactic treatment of chemotherapy-induced neutropenia
por: Waller, Cornelius F., et al.
Publicado: (2019)

Correction: Bonior, J., et al. Capsaicin-Sensitive Sensory Nerves Are Necessary for the Protective Effect of Ghrelin in Cerulein-Induced Acute Pancreatitis in Rats. Int. J. Mol. Sci. 2017, 18, 1402
por: Bonior, Joanna, et al.
Publicado: (2019)

1402. The Landscape of Infections Caused by Rare Bacterial Pathogens
por: Farid, Tahsin, et al.
Publicado: (2023)

Correction to: To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus
por: Heise, Tim, et al.
Publicado: (2019)

Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
por: Ingram, Rebecca L., et al.
Publicado: (2023)

Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars
por: Rosen, Lee S., et al.
Publicado: (2017)

Safety and efficacy of bevacizumab biosimilar in recurrent/ progressive glioblastoma
por: Kumar, Gunjesh, et al.
Publicado: (2021)

Correction: Inhibitory Activity of Bevacizumab to Differentiation of Retinoblastoma Cells
por: Heo, Jang Won, et al.
Publicado: (2012)

MYL2 as a potential predictive biomarker for rhabdomyosarcoma
por: Wang, Junning, et al.
Publicado: (2021)

The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
por: Goldschmidt, Jerome, et al.
Publicado: (2020)

Enhancement of 2,3-Butanediol Production by Klebsiella oxytoca PTCC 1402
por: Anvari, Maesomeh, et al.
Publicado: (2011)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
por: Cao, Di, et al.
Publicado: (2023)

Correction to: Efficacy and Safety of Biosimilar Romiplostim Versus Innovator Romiplostim in Patients with Chronic Immune Thrombocytopenia
por: Chandrakala, S., et al.
Publicado: (2023)

Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
por: Yanagi, Yasuo, et al.
Publicado: (2023)

Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab
por: Seo, Neungseon, et al.
Publicado: (2018)

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?
por: Monk, Bradley J., et al.
Publicado: (2017)

Intraocular Injection of StivantⓇ (A Biosimilar to Bevacizumab): A Case Series
por: Mirshahi, Ahmad, et al.
Publicado: (2021)

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
por: Gorbunova, Vera, et al.
Publicado: (2019)

Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
por: Lashay, Alireza, et al.
Publicado: (2020)

Pharmacokinetic and pharmacodynamic bioequivalence of biosimilar MYL‐1601D with US and European insulin aspart in healthy volunteers: A randomized, double‐blind, crossover, euglycaemic glucose clamp study
por: Hövelmann, Ulrike, et al.
Publicado: (2021)

P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
por: Dragieva, Y., et al.
Publicado: (2022)

Outer Membrane Vesicles of Helicobacter pylori TK1402 are Involved in Biofilm Formation
por: Yonezawa, Hideo, et al.
Publicado: (2009)

MYBPC2 and MYL1 as Significant Gene Markers for Rhabdomyosarcoma
por: Chen, Zihang, et al.
Publicado: (2021)

Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma
por: Matsushita, Katsunori, et al.
Publicado: (2021)

Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev(®)), a bevacizumab biosimilar, under extended in-use conditions
por: Weiser, Sarah, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qhnpu6t6n9u0r1257s7i9m11nk